PPARs in liver diseases and cancer: Epigenetic regulation by microRNAs

PPAR Research

Volumn , Issue , 2012, Pages

  Peyrou, Marion ^a   Ramadori, Pierluigi ^a   Bourgoin, Lucie ^a   Foti, Michelangelo ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTEROL; GLUCOSE; LIPID; MICRORNA; MICRORNA 145; MICRORNA 155; MICRORNA 200; MICRORNA 216; MICRORNA 217; MICRORNA 218; MICRORNA 224; MICRORNA 32; MICRORNA 33; MICRORNA 34; MICRORNA 342; MICRORNA 374; MICRORNA 431; MICRORNA 491; MICRORNA 590; MICRORNA 615; MICRORNA 708; MICRORNA 873; MICRORNA 92; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL LIVER DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; EPIGENETICS; FATTY LIVER; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HEPATITIS; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER ADENOMA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TRANSCRIPTION REGULATION;

EID: 84867370115     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/757803     Document Type: Review

References (174)

1. Williams R., Global challenges in liver disease. Hepatology 2006 44 3 521 526 2-s2.0-33748301260 10.1002/hep.21347 (Pubitemid 44433707)
2. Yip W. W., Burt A. D., Alcoholic liver disease. Seminars in Diagnostic Pathology 2006 23 3-4 149 160 2-s2.0-33846616400 10.1053/j.semdp.2006.11.002 (Pubitemid 46176510)
3. Marchesini G., Babini M., Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiologica 2006 54 2 229 239 2-s2.0-33745637207 (Pubitemid 43974287)
4. El-Serag H. B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012 142 6 1264.e1 1273.e1 2-s2.0-84860287080 10.1053/j.gastro.2011.12.061
5. Shire A. M., Roberts L. R., Prevention of hepatocellular carcinoma: progress and challenges. Minerva Gastroenterologica e Dietologica 2012 58 1 49 64 2-s2.0-84860308049
6. McGlynn K. A., London W. T., The global epidemiology of hepatocellular carcinoma: present and future. Clinics in Liver Disease 2011 15 2 223 243 2-s2.0-79959296814 10.1016/j.cld.2011.03.006
7. Wang C., Wang X., Gong G., Ben Q., Qiu W., Chen Y., Li G., Wang L., Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer 2012 130 7 1639 1648 2-s2.0-79960653870 10.1002/ijc.26165
8. Cornellà H., Alsinet C., Villanueva A., Molecular pathogenesis of hepatocellular carcinoma. Alcoholism 2011 35 5 821 825 2-s2.0-79955485194 10.1111/j.1530-0277.2010.01406.x
9. Contos M. J., Choudhury J., Mills A. S., Sanyal A. J., The histologic spectrum of nonalcoholic fatty liver disease. Clinics in Liver Disease 2004 8 3 481 500 2-s2.0-4344581329 10.1016/j.cld.2004.04.013 (Pubitemid 39141138)
10. Adams L. A., Angulo P., Recent concepts in non-alcoholic fatty liver disease. Diabetic Medicine 2005 22 9 1129 1133 2-s2.0-24044536090 10.1111/j.1464-5491.2005.01748.x (Pubitemid 41224168)
11. Caldwell S. H., Crespo D. M., Kang H. S., Al-Osaimi A. M. S., Obesity and hepatocellular carcinoma. Gastroenterology 2004 127 5 supplement 1 S97 S103 2-s2.0-7044235603 10.1053/j.gastro.2004.09.021 (Pubitemid 39423375)
12. El-Serag H. B., Hampel H., Javadi F., The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology 2006 4 3 369 380 2-s2.0-33644759114 10.1016/j.cgh.2005.12.007 (Pubitemid 43343895)
13. Farazi P. A., DePinho R. A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Reviews Cancer 2006 6 9 674 687 2-s2.0-33747830764 10.1038/nrc1934 (Pubitemid 44286000)
14. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Järvinen H., Svegliati-Baroni G., From the metabolic syndrome to NAFLD or vice versa? Digestive and Liver Disease 2010 42 5 320 330 2-s2.0-77951648486 10.1016/j.dld.2010.01.016
15. Larter C. Z., Chitturi S., Heydet D., Farrell G. C., A fresh look at NASH pathogenesis. Part 1: the metabolic movers. Journal of Gastroenterology and Hepatology 2010 25 4 672 690 2-s2.0-77950233673 10.1111/j.1440-1746.2010.06253.x
16. Malaguarnera M., Di Rosa M., Nicoletti F., Malaguarnera L., Molecular mechanisms involved in NAFLD progression. Journal of Molecular Medicine 2009 87 7 679 695 2-s2.0-67649448956 10.1007/s00109-009-0464-1
17. Lewis J. R., Mohanty S. R., Nonalcoholic fatty liver disease: a review and update. Digestive Diseases and Sciences 2010 55 3 560 578 2-s2.0-77949311823 10.1007/s10620-009-1081-0
18. Rombouts K., Marra F., Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Digestive Diseases 2010 28 1 229 235 2-s2.0-77952573691 10.1159/000282094
19. Michalik L., Wahli W., PPARs mediate lipid signaling in inflammation and cancer. PPAR Research 2008 23 7 351 363 2-s2.0-58149466606 10.1155/2008/134059 134059
20. Li G., Guo G. L., Role of class II nuclear receptors in liver carcinogenesis. Anti-Cancer Agents in Medicinal Chemistry 2011 11 6 529 542 2-s2.0-79959287496
21. Dharancy S., Louvet A., Hollebecque A., Desreumaux P., Mathurin P., Dubuquoy L., Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects. Gastroenterologie Clinique et Biologique 2008 32 3 339 350 2-s2.0-50349102093 10.1016/j.gcb.2008.01.029
22. Tailleux A., Wouters K., Staels B., Roles of PPARs in NAFLD: potential therapeutic targets. Biochimica et Biophysica Acta 2012 1821 5 809 818 2-s2.0-84859157277 10.1016/j.bbalip.2011.10.016
23. Kallwitz E. R., McLachlan A., Cotler S. J., Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2008 14 1 22 28 2-s2.0-39849099238 10.3748/wjg.14.22 (Pubitemid 351314322)
24. Pettinelli P., Videla L. A., Up-regulation of PPAR- γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. Journal of Clinical Endocrinology and Metabolism 2011 96 5 1424 1430 2-s2.0-79955650290 10.1210/jc.2010-2129
25. Lima-Cabello E., García-Mediavilla M. V., Miquilena-Colina M. E., Vargas-Castrillón J., Lozano-Rodríguez T., Fernández- Bermejo M., Olcoz J. L., González-Gallego J., García-Monzón C., Sánchez-Campos S., Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clinical Science 2011 120 6 239 250 2-s2.0-79251639639 10.1042/CS20100387
26. Morán-Salvador E., López-Parra M., García-Alonso V., Titos E., Martínez-Clemente M., González-Périz A., López-Vicario C., Barak Y., Arroyo V., Clària J., Role for PPAR γ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. The FASEB Journal 2011 25 8 2538 2550 2-s2.0-80051706346 10.1096/fj.10-173716
27. Yamazaki T., Shiraishi S., Kishimoto K., Miura S., Ezaki O., An increase in liver PPAR γ 2 is an initial event to induce fatty liver in response to a diet high in butter: PPAR γ 2 knockdown improves fatty liver induced by high-saturated fat. Journal of Nutritional Biochemistry 2011 22 6 543 553 2-s2.0-79955868038 10.1016/j.jnutbio.2010.04.009
28. Moya M., José Gómez-Lechón M., Castell J. V., Jover R., Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chemico-Biological Interactions 2010 184 3 376 387 2-s2.0-77949916811 10.1016/j.cbi.2010.01.008
29. Liu S., Wu H. J., Zhang Z. Q., Chen Q., Liu B., Wu J. P., Zhu L., The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. European Journal of Pharmacology 2011 650 1 384 389 2-s2.0-78649741621 10.1016/j.ejphar.2010.09.082
30. Zheng H., Li S., Ma L., Cheng L., Deng C., Chen Z., Xie C., Xiang M., Jiang W., Chen L., A novel agonist of PPAR- γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. European Journal of Pharmacology 2011 659 2-3 244 251 2-s2.0-79955939296 10.1016/j.ejphar.2011.03. 033
31. Gupte A. A., Liu J. Z., Ren Y., Minze L. J., Wiles J. R., Collins A. R., Lyon C. J., Pratico D., Finegold M. J., Wong S. T., Webb P., Baxter J. D., Moore D. D., Hsueh W. A., Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010 52 6 2001 2011 2-s2.0-78649560195 10.1002/hep.23941
32. Seo Y. S., Kim J. H., Jo N. Y., Choi K. M., Baik S. H., Park J. J., Kim J. S., Byun K. S., Bak Y. T., Lee C. H., Kim A., Yeon J. E., PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Journal of Gastroenterology and Hepatology 2008 23 1 102 109 2-s2.0-37249059359 10.1111/j.1440-1746.2006.04819.x (Pubitemid 350265194)
33. Lutchman G., Promrat K., Kleiner D. E., Heller T., Ghany M. G., Yanovski J. A., Liang T. J., Hoofnagle J. H., Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clinical Gastroenterology and Hepatology 2006 4 8 1048 1052 2-s2.0-33746340885 10.1016/j.cgh.2006.05.005 (Pubitemid 44118842)
34. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., Podevin P., Lacorte J. M., Bernhardt C., Bruckert E., Grimaldi A., Poynard T., Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008 135 1 100 110 2-s2.0-46349088361 10.1053/j.gastro.2008.03.078 (Pubitemid 351916703)
35. Sanyal A. J., Chalasani N., Kowdley K. V., McCullough A., Diehl A. M., Bass N. M., Neuschwander-Tetri B. A., Lavine J. E., Tonascia J., Unalp A., Van Natta M., Clark J., Brunt E. M., Kleiner D. E., Hoofnagle J. H., Robuck P. R., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England Journal of Medicine 2010 362 18 1675 1685 2-s2.0-77951874018 10.1056/NEJMoa0907929
36. Savage D. B., Tan G. D., Acerini C. L., Jebb S. A., Agostini M., Gurnell M., Williams R. L., Umpleby A. M., Thomas E. L., Bell J. D., Dixon A. K., Dunne F., Boiani R., Cinti S., Vidal-Puig A., Karpe F., Chatterjee V. K. V., O'Rahilly S., Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor- γ Diabetes 2003 52 4 910 917 2-s2.0-0344375097 10.2337/diabetes.52.4.910 (Pubitemid 36384259)
37. Hui Y., Yu-yuan L., Yu-qiang N., Wei-hong S., Yan-lei D., Xiao-bo L., Yong-jian Z., Effect of peroxisome proliferator-activated receptors- γ and co-activator-1 α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver International 2008 28 3 385 392 2-s2.0-39549113664 10.1111/j.1478-3231.2007. 01623.x (Pubitemid 351279587)
38. Rey J. W., Noetel A., Hardt A., Canbay A., Alakus H., zur Hausen A., Dienes H. P., Drebber U., Odenthal M., Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor γ 2 in patients with fatty liver diseases. World Journal of Gastroenterology 2010 16 46 5830 5837 2-s2.0-78650592847 10.3748/wjg.v16.i46.5830
39. Gawrieh S., Gawrieh S., Marion M. C., Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Digestive Diseases and Sciences 2012 57 4 952 957
40. Yang Z., Wen J., Li Q., Tao X., Ye Z., He M., Zhang W., Huang Y., Chen L., Ling C., Qu S., Hu R., PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Molecular and Cellular Endocrinology 2012 348 1 255 259 2-s2.0-80755189999 10.1016/j.mce.2011.09.001
41. Gupta A. C., Chaudhory A. K., Sukriti, Pande C., Sakhuja P., Singh Y., Basir S. F., Sarin S. K., Peroxisome proliferators-activated receptor γ 2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatology International 2011 5 1 575 580 2-s2.0-79952631265 10.1007/s12072-010-9225-z
42. Jong E. Y., Kyung M. C., Sei H. B., Kyoung O. K., Hyoung J. L., Ki H. P., Jin Y. K., Park J. J., Jae S. K., Bak Y. T., Kwan S. B., Chang H. L., Reduced expression of peroxisome proliferator-activated receptor- α may have an important role in the development of non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2004 19 7 799 804 2-s2.0-3242795074 10.1111/j.1440-1746.2004.03349.x (Pubitemid 38981403)
43. Lalloyer F., Wouters K., Baron M., Caron S., Vallez E., Vanhoutte J., Baugé E., Shiri-Sverdlov R., Hofker M., Staels B., Tailleux A., Peroxisome proliferator-activated receptor- α gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 7 1573 1579 2-s2.0-79959696573 10.1161/ATVBAHA.110.220525
44. Abdelmegeed M. A., Yoo S. H., Henderson L. E., Gonzalez F. J., Woodcroft K. J., Song B. J., PPAR α expression protects male mice from high fat-induced nonalcoholic fatty liver. Journal of Nutrition 2011 141 4 603 610 2-s2.0-79955504163 10.3945/jn.110.135210
45. Harano Y., Yasui K., Toyama T., Nakajima T., Mitsuyoshi H., Mimani M., Hirasawa T., Itoh Y., Okanoue T., Fenofibrate, a peroxisome proliferator- activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver International 2006 26 5 613 620 2-s2.0-33646812161 10.1111/j.1478-3231.2006. 01265.x
46. Larter C. Z., Yeh M. M., van Rooyen D. M., Brooling J., Ghatora K., Farrell G. C., Peroxisome proliferator-activated receptor- α agonist, Wy 14643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2012 27 2 341 350 2-s2.0-84856139907 10.1111/j.1440-1746.2011.06939.x
47. Qiu L., Lin J., Xu F., Gao Y., Zhang C., Liu Y., Luo Y., Yang J. Y., Inhibition of aldose reductase activates hepatic peroxisome proliferator- activated receptor- α and ameliorates hepatosteatosis in diabetic db/db mice. Experimental Diabetes Research 2012 2012 789730 2-s2.0-84855180612 10.1155/2012/789730
48. Larter C. Z., Yeh M. M., Cheng J., Williams J., Brown S., Dela Pena A., Bell-Anderson K. S., Farrell G. C., Activation of peroxisome proliferator-activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. Journal of Gastroenterology and Hepatology 2008 23 2 267 275 2-s2.0-39149132072 10.1111/j.1440-1746.2007.05157.x (Pubitemid 351257676)
49. Chen S., Li Y., Li S., Yu C., A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. Journal of Gastroenterology and Hepatology 2008 23 9 1415 1418 2-s2.0-49849093922 10.1111/j.1440-1746.2008.05523.x
50. Athyros V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., Kakafika A. I., Tziomalos K., Burroughs A. K., Elisaf M. S., Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current Medical Research and Opinion 2006 22 5 873 883 2-s2.0-33745046866 10.1185/ 030079906X104696 (Pubitemid 43875555)
51. Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J. A., A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease 2008 40 3 200 205 2-s2.0-38749085998 10.1016/j.dld.2007.10.002 (Pubitemid 351181792)
52. Wu H. T., Chen W., Cheng K. C., Ku P. M., Yeh C. H., Cheng J. T., Oleic acid activates peroxisome proliferator-activated receptor delta to compensate insulin resistance in steatotic cells. The Journal of nutritional biochemistry. In press
53. Lee C. H., Olson P., Hevener A., Mehl I., Chong L. W., Olefsky J. M., Gonzalez F. J., Ham J., Kang H., Peters J. M., Evans R. M., PPAR δ regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America 2006 103 9 3444 3449 2-s2.0-33644766913 10.1073/pnas.0511253103 (Pubitemid 43346488)
54. Sanderson L. M., Boekschoten M. V., Desvergne B., Müller M., Kersten S., Transcriptional profiling reveals divergent roles of PPAR α and PPAR β / δ in regulation of gene expression in mouse liver. Physiological Genomics 2010 41 1 42 52 2-s2.0-77949676576 10.1152/physiolgenomics.00127.2009
55. Sharma R., Torka P., Peroxisome proliferator-activated receptor- δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 2008 48 6 432 441 2-s2.0-58149390235 10.1002/hep.22602
56. Liu S., Hatano B., Zhao M., Yen C. C., Kang K., Reilly S. M., Gangl M. R., Gorgun C., Balschi J. A., Ntambi J. M., Lee C. H., Role of peroxisome proliferator-activated receptor δ / β in hepatic metabolic regulation. Journal of Biological Chemistry 2011 286 2 1237 1247 2-s2.0-78651384181 10.1074/jbc.M110.138115
57. Serrano-Marco L., Barroso E., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M., The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 2012 55 3 743 751 2-s2.0-84856705923 10.1007/s00125-011-2401-4
58. Barroso E., Rodríguez-Calvo R., Serrano-Marco L., Astudillo A. M., Balsinde J., Palomer X., Vázquez-Carrera M., The PPAR β / δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1 α -lipin 1-PPAR α pathway leading to increased fatty acid oxidation. Endocrinology 2011 152 5 1848 1859 2-s2.0-79955368052 10.1210/en.2010-1468
59. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., Yamazaki Y., Kuroda J., Shibata N., Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR δ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal of Pharmacology 2006 536 1-2 182 191 2-s2.0-33645891166 10.1016/j.ejphar.2006.02.028
60. Ye J. M., Tid-Ang J., Turner N., Zeng X. Y., Li H. Y., Cooney G. J., Wulff E. M., Sauerberg P., Kraegen E. W., PPAR δ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. British Journal of Pharmacology 2011 163 3 556 566 2-s2.0-79955919599 10.1111/j.1476-5381.2011.01240.x
61. Wu H. T., Chen C. T., Cheng K. C., Li Y. X., Yeh C. H., Cheng J. T., Pharmacological activation of peroxisome proliferator-activated receptor delta improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice. Hormone and Metabolic Research 2011 43 9 631 635 2-s2.0-79959640457 10.1055/s-0031-1280781
62. -/- mice. European Journal of Pharmacology 2009 622 13 45 51 2-s2.0-70349849654 10.1016/j.ejphar.2009.09.002
63. Sprecher D. L., Massien C., Pearce G., Billin A. N., Perlstein I., Willson T. M., Hassall D. G., Ancellin N., Patterson S. D., Lobe D. C., Johnson T. G., Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 359 365 2-s2.0-33846443997 10.1161/01.ATV.0000252790.70572.0c (Pubitemid 46143052)
64. Risérus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., Fang Z., Hegde P., Richards D., Sarov-Blat L., Strum J. C., Basu S., Cheeseman J., Fielding B. A., Humphreys S. M., Danoff T., Moore N. R., Murgatroyd P., O'Rahilly S., Sutton P., Willson T., Hassall D., Frayn K. N., Karpe F., Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008 57 2 332 339 2-s2.0-39649101196 10.2337/db07-1318
65. Bays H. E., Schwartz S., Littlejohn III T., Kerzner B., Krauss R. M., Karpf D. B., Choi Y.-J., Wang X., Naim S., Roberts B. K., MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. Journal of Clinical Endocrinology and Metabolism 2011 96 9 2889 2897 2-s2.0-80052539818 10.1210/jc.2011-1061
66. Miyahara T., Schrum L., Rippe R., Xiong S., Yee H. F., Motomura K., Anania F. A., Willson T. M., Tsukamoto H., Peroxisome proliferator-activated receptors and hepatic stellate cell activation. Journal of Biological Chemistry 2000 275 46 35715 35722 2-s2.0-0034680787 10.1074/jbc.M006577200
67. Marra F., Efsen E., Romanelli R. G., Caligiuri A., Pastacaldi S., Batignani G., Bonacchi A., Caporale R., Laffi G., Pinzani M., Gentilini P., Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000 119 2 466 478 2-s2.0-0033855572 (Pubitemid 30621997)
68. Zhang F., Lu Y., Zheng S., Peroxisome proliferator-activated receptor-gamma cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012 24 3 596 605
69. Nan Y. M., Fu N., Wu W. J., Liang B. L., Wang R. Q., Zhao S. X., Zhao J. M., Yu J., Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scandinavian Journal of Gastroenterology 2009 44 3 358 365 2-s2.0-61649105063 10.1080/00365520802530861
70. Tahan V., Eren F., Avsar E., Yavuz D., Yuksel M., Emekli E., Imeryuz N., Celikel C., Uzun H., Haklar G., Tozun N., Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Digestive Diseases and Sciences 2007 52 12 3465 3472 2-s2.0-35948957796 10.1007/s10620-007-9756-x (Pubitemid 350077190)
71. Lutchman G., Modi A., Kleiner D. E., Promrat K., Heller T., Ghany M., Borg B., Loomba R., Liang T. J., Premkumar A., Hoofnagle J. H., The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007 46 2 424 429 2-s2.0-34548306770 10.1002/hep.21661 (Pubitemid 47344777)
72. Yakaryilmaz F., Guliter S., Savas B., Erdem O., Ersoy R., Erden E., Akyol G., Bozkaya H., Ozenirler S., Effects of vitamin e treatment on peroxisome proliferator-activated receptor- α expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Internal Medicine Journal 2007 37 4 229 235 2-s2.0-33947400987 10.1111/j.1445-5994.2006. 01295.x (Pubitemid 46457497)
73. Shan W., Nicol C. J., Ito S., Bility M. T., Kennett M. J., Ward J. M., Gonzalez F. J., Peters J. M., Peroxisome proliferator-activated receptor- β / δ protects against chemically induced liver toxicity in mice. Hepatology 2008 47 1 225 235 2-s2.0-38649104434 10.1002/hep.21925 (Pubitemid 351171060)
74. Kang K., Reilly S. M., Karabacak V., Gangl M. R., Fitzgerald K., Hatano B., Lee C. H., Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metabolism 2008 7 6 485 495 2-s2.0-44349112305 10.1016/j.cmet.2008.04.002 (Pubitemid 351729204)
75. Hellemans K., Michalik L., Dittie A., Knorr A., Rombouts K., De Jong J., Heirman C., Quartier E., Schuit F., Wahli W., Geerts A., Peroxisome proliferator-activated receptor- β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003 124 1 184 201 2-s2.0-0037221210 10.1053/gast.2003.50015 (Pubitemid 36055351)
76. Kim K., Kim K. H., Ha E., Park J. Y., Sakamoto N., Cheong J., Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Letters 2009 583 17 2720 2726 2-s2.0-69249229453 10.1016/j.febslet.2009.07.034
77. Kim K. H., Hong S. P., Kim K., Park M. J., Kim K. J., Cheong J., HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPAR γ Biochemical and Biophysical Research Communications 2007 355 4 883 888 2-s2.0-33847633412 10.1016/j.bbrc.2007.02.044 (Pubitemid 46366910)
78. García-Mediavilla M. V., Pisonero-Vaquero S., Lima-Cabello E., Benedicto I., Majano P. L., Jorquera F., González-Gallego J., Sánchez-Campos S., Liver X receptor alpha-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Laboratory Investigation 2012 92 8 1191 1202 10.1038/labinvest.2012.88
79. Pazienza V., Vinciguerra M., Andriulli A., Mangia A., Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- γ in Huh-7 cells. Journal of General Virology 2010 91 1678 1686 2-s2.0-77954168704 10.1099/vir.0.020644-0
80. Niu Y. H., Yi R. T., Liu H. L., Chen T. Y., Zhang S. L., Zhao Y. R., Expression of COX-2 and PPARg in the livers of patients with acute on chronic HBV-related liver failure and their relationship with clinic parameters. Zhonghua Gan Zang Bing Za Zhi 2011 19 7 511 516
81. Kim K. H., Shin H. J., Kim K., Choi H. M., Rhee S. H., Moon H. B., Kim H. H., Yang U. S., Yu D. Y., Cheong J., Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007 132 5 1955 1967 2-s2.0-34247637220 10.1053/j.gastro.2007. 03.039 (Pubitemid 46677949)
82. Choi Y. H., Kim H. I., Seong J. K., Yu D. Y., Cho H., Lee M. O., Lee J. M., Ahn Y. H., Kim S. J., Park J. H., Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor γ through protein-protein interaction. FEBS Letters 2004 557 13 73 80 2-s2.0-9144250174 10.1016/S0014-5793(03)01449-2 (Pubitemid 38115872)
83. Ondracek C. R., McLachlan A., Role of peroxisome proliferator-activated receptor gamma coactivator 1alpha in AKT/PKB-mediated inhibition of hepatitis B virus biosynthesis. Journal of Virology 2011 85 22 11891 11900
84. Yoon S., Jung J., Kim T., Park S., Chwae Y. J., Shin H. J., Kim K., Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ controls hepatitis B virus replication. Virology 2011 409 2 290 298 2-s2.0-78650279970 10.1016/j.virol.2010.10.024
85. Wakui Y., Inoue J., Ueno Y., Fukushima K., Kondo Y., Kakazu E., Obara N., Kimura O., Shimosegawa T., Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor- γ ligand, rosiglitazone. Biochemical and Biophysical Research Communications 2010 396 2 508 514 2-s2.0-77952743760 10.1016/j.bbrc.2010.04.128
86. Crabb D. W., Galli A., Fischer M., You M., Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol 2004 34 1 35 38 2-s2.0-12744267799 10.1016/j.alcohol.2004.07.005
87. Moriya T., Naito H., Ito Y., Nakajima T., 'Hypothesis of seven balances': molecular mechanisms behind alcoholic liver diseases and association with PPAR α Journal of Occupational Health 2009 51 5 391 403 2-s2.0-74549189355 10.1539/joh.K9001
88. Wu C., Gilroy R., Taylor R., Olyaee M., Abdulkarim B., Forster J., O'Neil M., Damjanov I., Wan Y. J., Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology 2011 54 6 1966 1974
89. Dharancy S., Malapel M., Perlemuter G., Roskams T., Cheng Y., Dubuquoy L., Podevin P., Conti F., Canva V., Philippe D., Gambiez L., Mathurin P., Paris J. C., Schoonjans K., Calmus Y., Pol S., Auwerx J., Desreumaux P., Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005 128 2 334 342 2-s2.0-14944374003 10.1053/j.gastro.2004.11.016 (Pubitemid 40431087)
90. Goldwasser J., Cohen P. Y., Lin W., Kitsberg D., Balaguer P., Polyak S. J., Chung R. T., Yarmush M. L., Nahmias Y., Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. Journal of Hepatology 2011 55 5 963 971 2-s2.0-79960608394 10.1016/j.jhep.2011.02.011
91. Rakic B., Sagan S. M., Noestheden M., Bélanger S., Nan X., Evans C. L., Xie X. S., Pezacki J. P., Peroxisome proliferator-activated receptor α antagonism inhibits hepatitis C virus replication. Chemistry and Biology 2006 13 1 23 30 2-s2.0-30744432858 10.1016/j.chembiol.2005.10.006 (Pubitemid 43099921)
92. Pang M., de la Monte S. M., Longato L., Tong M., He J., Chaudhry R., Duan K., Ouh J., Wands J. R., PPAR δ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. Journal of Hepatology 2009 50 6 1192 1201 2-s2.0-67349255861 10.1016/j.jhep.2009.01.021
93. Yu J., Shen B., Chu E. S. H., Teoh N., Cheung K. F., Wu C. W., Wang S., Lam C. N. Y., Feng H., Zhao J., Cheng A. S. L., To K. F., Chan H. L. Y., Sung J. J. Y., Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010 51 6 2008 2019 2-s2.0-77952731389 10.1002/hep.23550
94. Schaefer K. L., Wada K., Takahashi H., Matsuhashi N., Ohnishi S., Wolfe M. M., Turner J. R., Nakajima A., Borkan S. C., Saubermann L. J., Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Research 2005 65 6 2251 2259 2-s2.0-20144389197 10.1158/0008-5472.CAN-04- 3037 (Pubitemid 40490134)
95. Yoshizawa K., Cioca D. P., Kawa S., Tanaka E., Kiyosawa K., Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002 95 10 2243 2251 2-s2.0-0037110628 10.1002/cncr.10906 (Pubitemid 35253388)
96. Cao L. Q., Wang X. L., Wang Q., Xue P., Jiao X. Y., Peng H. P., Lu H. W., Zheng Q., Chen X. L., Huang X. H., Fu X. H., Chen J. S., Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPAR γ signaling pathway. Acta Pharmacologica Sinica 2009 30 9 1316 1322 2-s2.0-70349139683 10.1038/aps.2009.119
97. Lee H. J., Su Y., Yin P. H., Lee H. C., Chi C. W., PPAR γ /PGC-1 α pathway in E-cadherin expression and motility of HepG2 cells. Anticancer Research 2009 29 12 5057 5063 2-s2.0-75149166058
98. Shim J., Kim B. H., Kim Y. I., Kim K. Y., Hwangbo Y., Jang J. Y., Dong S. H., Kim H. J., Chang Y. W., Chang R., The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. International Journal of Oncology 2010 36 1 223 231 2-s2.0-74549184686 10.3892/ijo-00000493
99. Borbath I., Leclercq I., Moulin P., Sempoux C., Horsmans Y., The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. European Journal of Cancer 2007 43 11 1755 1763 2-s2.0-34447251654 10.1016/j.ejca.2007.05.005 (Pubitemid 47042376)
100. Yu J., Qiao L., Zimmermann L., Ebert M. P. A., Zhang H., Lin W., Röcken C., Malfertheiner P., Farrell G. C., Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006 43 1 134 143 2-s2.0-33644792520 10.1002/hep.20994 (Pubitemid 43733600)
101. Hsu M. C., Huang C. C., Chang H. C., Hu T. H., Hung W. C., Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor γ ligands in vitro and in vivo. Clinical Cancer Research 2008 14 13 4045 4052 2-s2.0-48249136165 10.1158/1078-0432.CCR- 07-5040
102. Shah Y. M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F. J., Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Molecular and Cellular Biology 2007 27 12 4238 4247 2-s2.0-34250163202 10.1128/MCB.00317-07 (Pubitemid 46906549)
103. Gonzalez F. J., Shah Y. M., PPAR α: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008 246 1 2 8 2-s2.0-40049088000 10.1016/j.tox.2007.09.030
104. Peters J. M., Shah Y. M., Gonzalez F. J., The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature Reviews 2012 12 3 181 195
105. Peters J. M., Cattley R. C., Gonzalez F. J., Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997 18 11 2029 2033 2-s2.0-0031418657 10.1093/carcin/18.11.2029 (Pubitemid 28134725)
106. Hays T., Rusyn I., Burns A. M., Kennett M. J., Ward J. M., Gonzalez F. J., Peters J. M., Role of peroxisome proliferator-activated receptor- α (PPAR α) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 2005 26 1 219 227 2-s2.0-13444311098 10.1093/carcin/bgh285 (Pubitemid 40207717)
107. Youssef J., Badr M., Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis. TheScientificWorldJournal 2002 2 1491 1500 2-s2.0-0011446750
108. Corton J. C., Evaluation of the role of peroxisome proliferator-activated receptor α (PPAR α) in mouse liver tumor induction by trichloroethylene and metabolites. Critical Reviews in Toxicology 2008 38 10 857 875 2-s2.0-56449124307 10.1080/10408440802209796
109. Tanaka N., Moriya K., Kiyosawa K., Koike K., Aoyama T., Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor α in transgenic mice: implications for HCV-associated hepatocarcinogenesis. International Journal of Cancer 2008 122 1 124 131 2-s2.0-36749083957 10.1002/ijc.23056 (Pubitemid 350209986)
110. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F. J., Aoyama T., PPAR α activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. Journal of Clinical Investigation 2008 118 2 683 694 2-s2.0-38849184816 10.1172/JCI33594 (Pubitemid 351206557)
111. Morimura K., Cheung C., Ward J. M., Reddy J. K., Gonzalez F. J., Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 2006 27 5 1074 1080 2-s2.0-33646180263 10.1093/carcin/bgi329
112. Cheung C., Akiyama T. E., Ward J. M., Nicol C. J., Feigenbaum L., Vinson C., Gonzalez F. J., Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α Cancer Research 2004 64 11 3849 3854 2-s2.0-2542635631 10.1158/0008-5472.CAN-04- 0322 (Pubitemid 38697295)
113. Xu L., Han C., Lim K., Wu T., Cross-talk between peroxisome proliferator-activated receptor δ and cytosolic phospholipase A(2) α /cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Research 2006 66 24 11859 11868 2-s2.0-33846221464 10.1158/0008-5472.CAN-06-1445 (Pubitemid 46094198)
114. Suh H. N., Lee S. H., Lee M. Y., Lee Y. J., Lee J. H., Han H. J., Role of interleukin-6 in the control of DNA synthesis of hepatocytes: involvement of PKC, p44/42 MAPKs, and PPAR δ Cellular Physiology and Biochemistry 2008 22 5-6 673 684 2-s2.0-57649196331 10.1159/000185551
115. Leader J. E., Wang C., Fu M., Pestell R. G., Epigenetic regulation of nuclear steroid receptors. Biochemical Pharmacology 2006 72 11 1589 1596 2-s2.0-33750533592 10.1016/j.bcp.2006.05.024 (Pubitemid 44666731)
116. Mann J., Chu D. C. K., Maxwell A., Oakley F., Zhu N. L., Tsukamoto H., Mann D. A., MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010 138 2 705.e4 714.e4 2-s2.0-75149141045 10.1053/j.gastro.2009.10.002
117. Zhou Y., Jia X., Zhou M., Liu J., Egr-1 is involved in the inhibitory effect of leptin on PPAR γ expression in hepatic stellate cell in vitro. Life Sciences 2009 84 15-16 544 551 2-s2.0-62749188230 10.1016/j.lfs.2009.01.018
118. Xiao H., LeBlanc S. E., Wu Q., Konda S., Salma N., Marfella C. G., Ohkawa Y., Imbalzano A. N., Chromatin accessibility and transcription factor binding at the PPAR γ 2 promoter during adipogenesis is protein kinase A-dependent. Journal of Cellular Physiology 2011 226 1 86 93 2-s2.0-78049260100 10.1002/jcp.22308
119. Mitterberger M. C., Kim G., Rostek U., Levine R. L., Zwerschke W., Carbonic anhydrase III regulates peroxisome proliferator-activated receptor-gamma2. Experimental Cell Research 2012 318 8 877 886 2-s2.0-84859157159 10.1016/j.yexcr.2012.02.011
120. Farmer S. R., Transcriptional control of adipocyte formation. Cell Metabolism 2006 4 4 263 273 2-s2.0-33748942837 10.1016/j.cmet.2006.07.001 (Pubitemid 44430910)
121. Lobo G. P., Amengual J., Li H. N. M., Golczak M., Bonet M. L., Palczewski K., Von Lintig J., β β -carotene decreases peroxisome proliferator receptor γ activity and reduces lipid storage capacity of adipocytes in a β β -carotene oxygenase 1-dependent manner. Journal of Biological Chemistry 2010 285 36 27891 27899 2-s2.0-77956259307 10.1074/jbc.M110.132571
122. Wadosky K. M., Willis M. S., The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. American Journal of Physiology 2012 302 3 H515 H526
123. Juge-Aubry C. E., Hammar E., Siegrist-Kaiser C., Pernin A., Takeshita A., Chin W. W., Burger A. G., Meier C. A., Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor by phosphorylation of a ligand-independent trans-activating domain. Journal of Biological Chemistry 1999 274 15 10505 10510 2-s2.0-0033537827 10.1074/jbc.274.15.10505 (Pubitemid 29180929)
124. Gilde A. J., Van Bilsen M., Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiologica Scandinavica 2003 178 4 425 434 2-s2.0-0042405041 10.1046/j.1365-201X.2003.01161.x (Pubitemid 36960434)
125. Yu S., Reddy J. K., Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et Biophysica Acta 2007 1771 8 936 951 2-s2.0-34547604561 10.1016/j.bbalip.2007.01.008 (Pubitemid 47198542)
126. Grimson A., Farh K. K. H., Johnston W. K., Garrett-Engele P., Lim L. P., Bartel D. P., MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Molecular Cell 2007 27 1 91 105 2-s2.0-34250805982 10.1016/j.molcel.2007.06.017 (Pubitemid 46991392)
127. Lee R. C., Feinbaum R. L., Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 75 5 843 854 2-s2.0-0027751663 10.1016/0092-8674(93)90529-Y (Pubitemid 24014542)
128. Filipowicz W., Bhattacharyya S. N., Sonenberg N., Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics 2008 9 2 102 114 2-s2.0-38349169664 10.1038/nrg2290
129. Saini H. K., Griffiths-Jones S., Enright A. J., Genomic analysis of human microRNA transcripts. Proceedings of the National Academy of Sciences of the United States of America 2007 104 45 17719 17724 2-s2.0-36749026287 10.1073/pnas.0703890104 (Pubitemid 350210901)
130. Lee Y., Kim M., Han J., Yeom K. H., Lee S., Baek S. H., Kim V. N., MicroRNA genes are transcribed by RNA polymerase II. The EMBO Journal 2004 23 20 4051 4060 2-s2.0-8144225486 10.1038/sj.emboj.7600385 (Pubitemid 39472426)
131. Breving K., Esquela-Kerscher A., The complexities of microRNA regulation: mirandering around the rules. International Journal of Biochemistry and Cell Biology 2010 42 8 1316 1329 2-s2.0-77954385729 10.1016/j.biocel.2009.09.016
132. Zeng Y., Cullen B. R., Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. Journal of Biological Chemistry 2005 280 30 27595 27603 2-s2.0-23044502585 10.1074/jbc.M504714200 (Pubitemid 41076871)
133. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
134. Yi R., Qin Y., Macara I. G., Cullen B. R., Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and Development 2003 17 24 3011 3016 2-s2.0-0347361541 10.1101/gad.1158803 (Pubitemid 38040764)
135. Lund E., Güttinger S., Calado A., Dahlberg J. E., Kutay U., Nuclear export of microRNA precursors. Science 2004 303 5654 95 98 2-s2.0-0347988235 10.1126/science.1090599 (Pubitemid 38055779)
136. Melo S. A., Esteller M., A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle 2011 10 6 922 925
137. Zhang H., Kolb F. A., Jaskiewicz L., Westhof E., Filipowicz W., Single processing center models for human Dicer and bacterial RNase III. Cell 2004 118 1 57 68 2-s2.0-3142613181 10.1016/j.cell.2004.06.017 (Pubitemid 38902814)
138. Gregory R. I., Chendrimada T. P., Cooch N., Shiekhattar R., Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005 123 4 631 640 2-s2.0-27744537851 10.1016/j.cell.2005.10.022 (Pubitemid 41608466)
139. Kawamata T., Seitz H., Tomari Y., Structural determinants of miRNAs for RISC loading and slicer-independent unwinding. Nature Structural and Molecular Biology 2009 16 9 953 960 2-s2.0-69949127421 10.1038/nsmb.1630
140. Park C. Y., Choi Y. S., McManus M. T., Analysis of microRNA knockouts in mice. Human Molecular Genetics 2010 19 R2 R169 R175 2-s2.0-79951865331
141. Baek D., Villén J., Shin C., Camargo F. D., Gygi S. P., Bartel D. P., The impact of microRNAs on protein output. Nature 2008 455 7209 64 71 2-s2.0-49949116902 10.1038/nature07242
142. Sood P., Krek A., Zavolan M., Macino G., Rajewsky N., Cell-type-specific signatures of microRNAs on target mRNA expression. Proceedings of the National Academy of Sciences of the United States of America 2006 103 8 2746 2751 2-s2.0-33644499134 10.1073/pnas.0511045103
143. Gao Y., Schug J., McKenna L. B., Le Lay J., Kaestner K. H., Greenbaum L. E., Tissue-specific regulation of mouse microRNA genes in endoderm-derived tissues. Nucleic Acids Research 2011 39 2 454 463 2-s2.0-79551473619 10.1093/nar/gkq782
144. Thum T., MicroRNA therapeutics in cardiovascular medicine. EMBO Molecular Medicine 2012 4 1 3 14
145. Kantharidis P., Wang B., Carew R. M., Lan H. Y., Diabetes complications: the microRNA perspective. Diabetes 2011 60 7 1832 1837 2-s2.0-80052102044 10.2337/db11-0082
146. Rottiers V., Naar A. M., MicroRNAs in metabolism and metabolic disorders. Nature Reviews Molecular Cell Biology 2012 13 4 239 250
147. Sonntag K. C., MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Research 2010 1338 48 57 2-s2.0-77952675535 10.1016/j.brainres.2010.03.106
148. O'Connell R. M., Rao D. S., Chaudhuri A. A., Baltimore D., Physiological and pathological roles for microRNAs in the immune system. Nature Reviews Immunology 2010 10 2 111 122 2-s2.0-75649139134 10.1038/nri2708
149. Medina P. P., Nolde M., Slack F. J., OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010 467 7311 86 90 2-s2.0-77956339881 10.1038/nature09284
150. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., Croce C. M., Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E μ -miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 7024 7029 2-s2.0-33646471662 10.1073/pnas.0602266103
151. Xu H., He J. H., Xiao Z. D., Zhang Q. Q., Chen Y. Q., Zhou H., Qu L. H., Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010 52 4 1431 1442 2-s2.0-77957954445 10.1002/hep.23818
152. Krützfeldt J., Rajewsky N., Braich R., Rajeev K. G., Tuschl T., Manoharan M., Stoffel M., Silencing of microRNAs in vivo with antagomirs Nature 2005 438 7068 685 689 2-s2.0-28444469246 10.1038/nature04303 (Pubitemid 41740580)
153. Castoldi M., Spasic M. V., Altamura S., Elmén J., Lindow M., Kiss J., Stolte J., Sparla R., D'Alessandro L. A., Klingmüller U., Fleming R. E., Longerich T., Gröne H. J., Benes V., Kauppinen S., Hentze M. W., Muckenthaler M. U., The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. Journal of Clinical Investigation 2011 121 4 1386 1396 2-s2.0-79953316619 10.1172/JCI44883
154. Ferland-McCollough D., Ozanne S. E., Siddle K., Willisand A. E., Bushell M., The involvement of microRNAs in type 2 diabetes. Biochemical Society Transactions 2010 38 6 1565 1570 2-s2.0-78649727507 10.1042/BST0381565
155. Haybaeck J., Zeller N., Heikenwalder M., The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Medical Weekly 2011 141 w13287
156. Bala S., Szabo G., MicroRNA signature in alcoholic liver disease. International Journal of Hepatology 2012 2012 498232
157. Waidmann O., Bihrer V., Pleli T., Farnik H., Berger A., Zeuzem S., Kronenberger B., Piiper A., Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 2012 19 2 e58 e65 2-s2.0-84855826136 10.1111/j.1365-2893.2011.01536.x
158. Henke J. I., Goergen D., Zheng J., Song Y., Schüttler C. G., Fehr C., Jünemann C., Niepmann M., MicroRNA-122 stimulates translation of hepatitis C virus RNA. The EMBO Journal 2008 27 24 3300 3310 2-s2.0-58049217312 10.1038/emboj.2008.244
159. Jiang X., Tsitsiou E., Herrick S. E., Lindsay M. A., MicroRNAs and the regulation of fibrosis. FEBS Journal 2010 277 9 2015 2021 2-s2.0-77951219188 10.1111/j.1742-4658.2010.07632.x
160. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R., Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology 2012 23 3 458 469 2-s2.0-84857979740 10.1681/ASN.2011050485
161. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J., MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008 47 6 1955 1963 2-s2.0-46249083024 10.1002/hep.22256 (Pubitemid 351952843)
162. Wang Y., Lee A. T. C., Ma J. Z. I., Wang J., Ren J., Yang Y., Tantoso E., Li K. B., Ooi L. L. P. J., Tan P., Lee C. G. L., Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. Journal of Biological Chemistry 2008 283 19 13205 13215 2-s2.0-45149128115 10.1074/jbc.M707629200
163. Zheng L., Lv G. C., Sheng J., Yang Y. D., Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR- α expression, a novel mechanism for the pathogenesis of NAFLD. Journal of Gastroenterology and Hepatology 2010 25 1 156 163 2-s2.0-73449136157 10.1111/j.1440-1746.2009.05949.x
164. Kida K., Nakajima M., Mohri T., Oda Y., Takagi S., Fukami T., Yokoi T., PPARalpha is regulated by miR-21 and miR-27b in human liver. Pharmaceutical Research 2011 28 10 2467 2476
165. Gatfield D., Le Martelot G., Vejnar C. E., Gerlach D., Schaad O., Fleury-Olela F., Ruskeepää A. L., Oresic M., Esau C. C., Zdobnov E. M., Schibler U., Integration of microRNA miR-122 in hepatic circadian gene expression. Genes and Development 2009 23 11 1313 1326 2-s2.0-66149167562 10.1101/gad.1781009
166. Karbiener M., Fischer C., Nowitsch S., Opriessnig P., Papak C., Ailhaud G., Dani C., Amri E. Z., Scheideler M., MicroRNA miR-27b impairs human adipocyte differentiation and targets PPAR γ Biochemical and Biophysical Research Communications 2009 390 2 247 251 2-s2.0-70350125874 10.1016/j.bbrc.2009.09.098
167. Kim S. Y., Kim A. Y., Lee H. W., Son Y. H., Lee G. Y., Lee J.-W., Lee Y. S., Kim J. B., MiR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochemical and Biophysical Research Communications 2010 392 3 323 328 2-s2.0-76349089521 10.1016/j.bbrc.2010.01.012
168. Lee E. K., Lee M. J., Abdelmohsen K., Kim W., Kim M. M., Srikantan S., Martindale J. L., Hutchison E. R., Kim H. H., Marasa B. S., Selimyan R., Egan J. M., Smith S. R., Fried S. K., Gorospe M., MiR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor γ expression. Molecular and Cellular Biology 2011 31 4 626 638 2-s2.0-79251544878 10.1128/MCB.00894-10
169. Martinelli R., Nardelli C., Pilone V., Buonomo T., Liguori R., Castanò I., Buono P., Masone S., Persico G., Forestieri P., Pastore L., Sacchetti L., MiR-519d overexpression is associated with human obesity. Obesity 2010 18 11 2170 2176 2-s2.0-78049317991 10.1038/oby.2009.474
170. Wang J., Song Y., Zhang Y., Xiao H., Sun Q., Hou N., Guo S., Wang Y., Fan K., Zhan D., Zha L., Cao Y., Li Z., Cheng X., Zhang Y., Yang X., Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Research 2012 22 3 516 527 2-s2.0-84857791711 10.1038/cr.2011.132
171. Jennewein C., Von Knethen A., Schmid T., Brüne B., MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor γ (PPAR γ) mRNA destabilization. Journal of Biological Chemistry 2010 285 16 11846 11853 2-s2.0-77951219696 10.1074/jbc.M109.066399
172. Iliopoulos D., Malizos K. N., Oikonomou P., Tsezou A., Integrative MicroRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS ONE 2008 3 11 2-s2.0-56649084972 10.1371/journal.pone.0003740 e3740
173. Zhou J., Wang K. C., Wu W., Subramaniam S., Shyy J. Y. J., Chiu J. J., Li J. Y. S., Chien S., MicroRNA-21 targets peroxisome proliferators-activated receptor- α in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proceedings of the National Academy of Sciences of the United States of America 2011 108 25 10355 10360 2-s2.0-79959973595 10.1073/pnas.1107052108
174. Tong J. L., Zhang C. P., Nie F., Xu X. T., Zhu M. M., Xiao S. D., Ran Z. H., MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin- resistant human colon cancer cells. FEBS Letters 2011 585 22 3560 3568 2-s2.0-80855144808 10.1016/j.febslet.2011.10.021